The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment
Abstract
To the editor: There is an expanding armory of novel chemotherapeutic agents used in hematologic cancers, many of which cause problematic gastrointestinal (GI) side effects. These often mandate dose reduction or even cessation of treatment. Few studies have investigated the causes for this GI
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Drugs that induce targeted protein degradation, such as thalidomide analogues, have a number of unique pharmacological features in comparison with conventional enzyme inhibitors58,138–140.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [140]
In the citing paper
“In parallel to the discovery that thalidomide analogues act as ‘molecular glue’ degraders, heterobifunctional proteolysis targeting chimeras (PROTACs), which are based on a similar principle and consist of an E3 ubiquitin ligase-recruiting element linked to a target-binding moiety, have advanced from being proof-of-concept molecules to investigational anticancer drugs (BOX 3)140.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [140]
Citations
Cites
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., et al. (2005) · Blood · doi:10.1182/blood-2005-07-2817 · Cited by 648
Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523
Andreyev, J. N., Davidson, S. E., Gillespie, C., Allum, W., & Swarbrick, E. T. (2011) · Gut · doi:10.1136/gutjnl-2011-300563 · Cited by 293
Andreyev, J. N., Benton, B. E., Lalji, A., Norton, C. S., Mohammed, K., Gage, H., Pennert, K. M., & Lindsay, J. O. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61648-7 · Cited by 145
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
Dimopoulos, M. A., Palumbo, A. P., Attal, M., Beksaç, M., Davies, F. E., Delforge, M., Einsele, H., Hájek, R., Harousseau, J., da Costa, F. L., et al. (2011) · Leukemia · doi:10.1038/leu.2011.3 · Cited by 117
Self-citationBile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy
Walters, J. R. F. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2014.32 · Cited by 104
Facon, T. T. F., Dimopoulos, M. A., Dispenzieri, A. A., et al. (2013) · Blood · doi:10.1182/blood.v122.21.2.2 · Cited by 59
Bajor, A., Kilander, A. F., Sjövall, H., Rudling, M., & Ung, K. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0256-4 · Cited by 20
Flagged first, then by citations
Cited by
Sorted by citations
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137
Metadata
- Authors
- Pawlyn, C., Khan, M. S., Muls, A., Sriskandarajah, P., Kaiser, M. F., Davies, F. E., Morgan, G. J., & Andreyev, H. J. N.
- Affiliations
- Institute of Cancer Research (GB)
- University Hospital of Wales (GB)
- Royal Marsden Hospital (GB)
- Department of Gastroenterology, Royal Marsden Hospital, London, United Kingdom
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2014-10-09
- Volume
- 124
- Issue
- 15
- Pages
- 2467-2468
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2122728054
- Cited by
- 66
- References
- 8
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4 · 2023: 4 · 2022: 9 · 2021: 10 · 2020: 7 · 2019: 5 · 2018: 7 · 2017: 9 · 2016: 3 · 2015: 5
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Cancer Research UK
- National Institute for Health and Care Research (ACF-2012-22-005)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- lenalidomide, diarrhea, multiple myeloma, bile acid malabsorption, gastrointestinal adverse effects, chemotherapy side effects, treatment response
- MeSH terms
- Lenalidomide, Aged, Bile Acids and Salts, Diarrhea, Female, Humans, Malabsorption Syndromes, Male, Middle Aged, Multiple Myeloma, Thalidomide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
